Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging

Circulation

Volumn 119, Issue 21, 2009, Pages 2789-2797

  Dai, Dao Fu ^a   Santana, Luis F ^a   Vermulst, Marc ^a   Tomazela, Daniela M ^a   Emond, Mary J ^a   MacCoss, Michael J ^a   Gollahon, Katherine ^a   Martin, George M ^a   Loeb, Lawrence A ^a   Ladiges, Warren C ^a   Rabinovitch, Peter S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aging; Diastole; Mitochondria; Oxidant stress; Survival

Indexed keywords

CATALASE; MITOCHONDRIAL DNA; PROTEIN; SERCA 2 PROTEIN; UNCLASSIFIED DRUG; ATP2A2 PROTEIN, MOUSE; HYBRID PROTEIN; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRANSCRIPTION FACTOR NFAT;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; GENE DELETION; GENE MUTATION; HEART; HEART FUNCTION; HEART LEFT VENTRICLE MASS; LIFESPAN; MALE; MITOCHONDRION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CALCIUM SIGNALING; CHEMISTRY; ECHOGRAPHY; ENZYMOLOGY; FIBROSIS; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; METABOLISM; MOUSE; MUTATION; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; ULTRASTRUCTURE;

AGING; ANIMALS; CALCIUM SIGNALING; CATALASE; DIASTOLE; DNA, MITOCHONDRIAL; FIBROSIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA, HEART; MODELS, CARDIOVASCULAR; MUTATION; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; ORGAN SPECIFICITY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECOMBINANT FUSION PROTEINS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67649204729     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.822403     Document Type: Article

References (30)

1. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises, part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346-354.
2. Murphy SW. Diastolic dysfunction. Curr Treat Options Cardiovasc Med. 2004;6:61-68.
3. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483-495.
4. Vermulst M, Bielas JH, Kujoth GC, Ladiges WC, Rabinovitch PS, Prolla TA, Loeb LA. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet. 2007;39:540-543.
5. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science. 2005;308:1909-1911.
6. Dilly KW, Rossow CF, Votaw VS, Meabon JS, Cabarrus JL, Santana LF. Mechanisms underlying variations in excitation-contraction coupling across the mouse left ventricular free wall. J Physiol. 2006; 572:227-241.
7. Etches V, Frank J, Di Ruggiero E, Manuel D. Measuring population health: a review of indicators. Annu Rev Public Health. 2006;27:29-55.
8. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A, Striker LJ, Striker GE. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol. 2003;162: 1339-1348.
9. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr. 2004;17:290-297.
10. Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS, Prolla TA, Loeb LA. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet. 2008;40:392-394.
11. Bielas JH, Loeb LA. Quantification of random genomic mutations. Nat Methods. 2005;2:285-290.
12. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127:397-408.
13. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intra-cellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
14. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1-and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol. 2001;21:7460-7469.
15. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
16. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
17. Date MO, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y, Hirotani S, Matsumura Y, Hori M, Tada M, Otsu K. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol. 2002; 39:907-912.
18. Matsushima S, Ide T, Yamato M, Matsusaka H, Hattori F, Ikeuchi M, Kubota T, Sunagawa K, Hasegawa Y, Kurihara T, Oikawa S, Kinugawa S, Tsutsui H. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 2006;113:1779-1786.
19. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007; 6:617-635.
20. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res. 2005;97:967-974.
21. Inserra F, Romano L, Ercole L, de Cavanagh EM, Ferder L. Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension. 1995;25:437-442.
22. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol. 2007;293:H1351-H1358.
23. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angio-tensin II mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102: 488-496.
24. Lim CC, Apstein CS, Colucci WS, Liao R. Impaired cell shortening and relengthening with increased pacing frequency are intrinsic to the senescent mouse cardiomyocyte. J Mol Cell Cardiol. 2000;32: 2075-2082.
25. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises, part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490-497.
26. Houser SR, Piacentino V 3rd, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol. 2000;32:1595-1607.
27. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM. Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension. 2005;46:426-432.
28. Ren J, Li Q, Wu S, Li SY, Babcock SA. Cardiac overexpression of antioxidant catalase attenuates aging-induced cardiomyocyte relaxation dysfunction. Mech Ageing Dev. 2007;128:276-285.
29. Treuting PM, Linford NJ, Knoblaugh SE, Emond MJ, Morton JF, Martin GM, Rabinovitch PS, Ladiges WC. Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci. 2008;63:813-822.
30. Butler RN, Miller RA, Perry D, Carnes BA, Williams TF, Cassel C, Brody J, Bernard MA, Partridge L, Kirkwood T, Martin GM, Olshansky SJ. New model of health promotion and disease prevention for the 21st century. BMJ. 2008;337:a399.